v3.26.1
Sale of Future IMDELLTRA® Royalties - Schedule of Royalty Sale Liability Activity (Details)
$ in Thousands
3 Months Ended
Mar. 31, 2026
USD ($)
Royalty Financing Obligation [Roll Forward]  
Balance at December 31, 2025 $ 3,827,379
Balance at March 31, 2026 3,793,177
Royalty Payments  
Royalty Financing Obligation [Roll Forward]  
Balance at December 31, 2025 906,956
Debt portion of royalties recognized and settled to Royalty Pharma (2,557)
Balance at March 31, 2026 $ 904,399